The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model

Background: The farnesoid X receptor (FXR) influences hepatic metabolism, inflammation and liver fibrosis as key components of non-alcoholic steatohepatitis (NASH). We studied the effects of the non-steroidal FXR agonist cilofexor (formerly GS-9674) on portal pressure and fibrosis in experimental NA...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Philipp Schwabl, Eva Hambruch, Grant R. Budas, Paul Supper, Michael Burnet, John T. Liles, Manfred Birkel, Ksenia Brusilovskaya, Philipp Königshofer, Markus Peck-Radosavljevic, William J. Watkins, Michael Trauner, David G. Breckenridge, Claus Kremoser, Thomas Reiberger
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2021-01-01
coleção:	Biomedicines
Assuntos:	NASH FXR cilofexor portal hypertension fibrosis rats
Acesso em linha:	https://www.mdpi.com/2227-9059/9/1/60
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!